Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

KURA vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKRO Captures Overall Composite Edge (60.0 BUY vs 72.4 BUY), While KURA Leads 4–1 on Growth & Valuation Pillars

AKRO Overall Winner 6-Pillar Tally: KURA 4 – 1 AKRO (1 Tie) Matrix Metrics: KURA 2 – 5 AKRO

As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Kura Oncology, Inc. (KURA) on higher Unified Composite conviction (60.0/100 BUY vs. 72.4/100 BUY) after splitting the core matrix 5–2 (led by Profitability & Quality), while KURA wins 4–1 across the 6-pillar growth and valuation breakdown. KURA trades at $6.91 (N/M Forward P/E, -394.3% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (72.4/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -394.3% operating margin) and revenue trajectory (+0.0% vs. +10.1% YoY).
  • Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KURA vs AKRO
KURA NASDAQ
Kura Oncology, Inc.
Pharmaceutical Preparations
$6.91
-5.99% 1D
Market Cap $675.3M
TTM Revenue $79M
Forward P/E N/M
Beta / 30D Vol 1.37β · 107% Vol
Unified Composite Score
72.4 / 100 BUY
Tech 81.0 Fund 75.0 Flow 67.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.4%), weak momentum, RSI 34
RSI-14: 33.6 · SMA20: $8.33 · SMA50: $9.68
AKRO NASDAQ Head-to-Head Winner
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (KURA 4 – 1 AKRO)

Columns: Metric · KURA · AKRO
1. Valuation Multiples KURA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 8.1x N/M
2. Growth & Scale KURA
Revenue Growth (YoY) +10.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $79M N/A
Market Cap $675.3M $4.5B
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin -394.3% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -224.8% -34.5%
4. Balance Sheet & Cash Flow KURA
Cash Generation (TTM) -$89M N/A
Cash Flow Margin -112.4% N/A
Net Cash / Leverage $32M Net Cash $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KURA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 120.5% (20th %ile) 7.3% (30th %ile)
Put/Call OI Skew 1.04x (Balanced) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KURA (2) vs AKRO (5)
Institutional Metric KURA AKRO Criterion Row Edge
Market Capitalization
Scale
$675.3M $4.5B Larger Scale AKRO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+10.1% +0.0% Higher Growth KURA
Operating Margin (TTM)
Profitability
-394.3% 0.0% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-224.8% -34.5% Higher ROE AKRO
52-Week Range Position
Momentum
2% ($7–$14) 90% ($21–$58) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
1.37β · 107% Vol 0.90β · 2% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
72.4 / 100 (BUY) 60.0 / 100 (BUY) Higher Composite KURA
Trailing 12M Revenue (USD)
Operating Scale
$79M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$89M ($32M Net Cash) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KURA +2.26 pp
KURA: +2.83% · AKRO: +0.57%
3M Horizon KURA +2.26 pp
KURA: +2.83% · AKRO: +0.57%
6M Horizon KURA +2.26 pp
KURA: +2.83% · AKRO: +0.57%
1Y Horizon KURA +2.26 pp
KURA: +2.83% · AKRO: +0.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KURA vs AKRO. Trailing 12-month operating profitability (KURA -394.3% vs AKRO 0.0%) and valuation multiples (KURA N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KURA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$79M
Gross MarginN/A
Op. Margin-394.3%
ROE / Fwd P/E-224.8% · N/M
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KURA BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 120.5%
IV Percentile 20th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $675.3M market capitalization and -394.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KURA vs AKRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Kura Oncology, Inc. (KURA) on higher Unified Composite conviction (60.0/100 BUY vs. 72.4/100 BUY) after splitting the core matrix 5–2 (led by Profitability & Quality), while KURA wins 4–1 across the 6-pillar growth and valuation breakdown. KURA trades at $6.91 (N/M Forward P/E, -394.3% operating margin) versus AKRO at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (72.4/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–2 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -394.3% operating margin) and revenue trajectory (+0.0% vs. +10.1% YoY). Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KURA leads the Growth & Scale pillar: KURA posts +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, KURA generates $79M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, KURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

KURA screens cheaper on headline valuation multiples. KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.1x EV/Revenue (-112.4% FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KURA (-224.8% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, KURA carries 120.5% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 107% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.